Stay updated on CABozantinib in NSCLC MET Clinical Trial

Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.5, indicating a new release. However, the previous information regarding the modernization of ClinicalTrials.gov data ingest has been removed.
    Difference
    1%
    Check dated 2025-07-03T12:29:32.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1%
    Check dated 2025-06-19T05:24:54.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-11T21:01:16.000Z thumbnail image
  5. Check
    33 days ago
    No Change Detected
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-28T13:32:09.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T00:16:36.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding a phase II trial for Non-Small Cell Lung Cancer (NSCLC) and the addition of a new version revision. Notably, the principal investigator's name has been retained, but the detailed eligibility criteria and treatment protocols have been deleted.
    Difference
    29%
    Check dated 2025-04-22T18:14:12.000Z thumbnail image

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.